Johnson & Johnson (JNJ)

A name that's often ignored by investors due to its limited historic growth is evolving into a solid income-growth prospect.

There are plenty of reasons to love these companies.

FDA grants De Novo authorization for Johnson & Johnson's OTTAVA robotic surgical system for general surgery procedures.

While AI stocks correct, Johnson & Johnson, Altria, Coca-Cola, JPMorgan, and Apple are quietly trading near 52-week or all-time highs ahead of earnings.

PJP delivered a higher return over the past year -- but IYH charges lower fees and pays a higher dividend yield.

J&J has more than 28 sources of blockbuster revenue.

They can help stabilize your portfolio in these otherwise volatile times.

A tech selloff hit the S&P 500 and NASDAQ this week while energy and financial stocks gained; MarketBeat analysts recap Micron, Netflix, Broadcom, Apple and more ahead of Alphabet's earnings.

The reasons why RBC Capital Markets maintains its stock rating.

One generates steady cash flow with a lower valuation; the other is growing at 45% but carries higher leverage.

IHE concentrates on giants such as Johnson & Johnson and Eli Lilly, while XPH spreads risk across 65 holdings with different volatility profiles.

Johnson & Johnson (NYSE:JNJ) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to

Investors didn't seem to think so after the company published it.

Johnson & Johnson's post-earnings pullback follows a revenue and EPS beat, raised guidance, and analyst price target increases, with talc litigation remaining the key risk to watch.